Role of prostaglandins in hyperprostaglandin E syndrome and in selected renal tubular disorders
- PMID: 3153322
- DOI: 10.1007/BF00849259
Role of prostaglandins in hyperprostaglandin E syndrome and in selected renal tubular disorders
Abstract
Renal and systemic prostanoid activity was assessed in various renal tubular disorders, using mass spectrometric determination of urinary excretion rates of primary prostaglandins (PGE2, PGF2 alpha, PGI2, and TXA2) and their systemically produced index metabolites. Only PGE2 levels (normal range: 2.0-16.4 ng/h per 1.73 m2) are elevated in Bartter syndrome (median: 43.4, range: 6.7-166.3), nephrogenic diabetes insipidus (46.2, 12.1-1290), Fanconi syndrome (96.6, 19.3-135.5), and in a complex tubular disorder in premature infants (40.7, 22.3-132.1), for which the term hyperprostaglandin E syndrome has been introduced. In this disorder with a Bartter-syndrome-like tubulopathy, the systemic features of the disease such as fever, diarrhoea and osteopenia with hypercalciuria were associated with increased systemic PGE2 activity. In most patients the urinary excretion rate of the systemic index metabolite of PGE2 (PGE-M) was markedly elevated (1028, 285-4709; normal range: 104-664 ng/h per 1.73 m2). Hypercalciuria per se was associated neither with increased renal nor with systemic PGE2 hyperactivity. Most problems in infants with hyperprostaglandin E syndrome could be controlled by long-term indomethacin treatment in contrast to the moderate and partial effect of this treatment in patients with Fanconi syndrome. Thus increased PGE2 synthesis plays a major role in the pathogenesis of hyperprostaglandin E syndrome, while in Fanconi syndrome PGE2 hyperactivity in the kidney is a secondary event and only aggravates the water and electrolyte wastage.
Similar articles
-
Congenital hypokalemia with hypercalciuria in preterm infants: a hyperprostaglandinuric tubular syndrome different from Bartter syndrome.J Pediatr. 1985 Nov;107(5):694-701. doi: 10.1016/s0022-3476(85)80395-4. J Pediatr. 1985. PMID: 3863906
-
Calcium homeostasis and hypercalciuria in hyperprostaglandin E syndrome.J Pediatr. 1992 Apr;120(4 Pt 1):546-54. doi: 10.1016/s0022-3476(05)82480-1. J Pediatr. 1992. PMID: 1340758 Clinical Trial.
-
Marked reduction of Tamm-Horsfall protein synthesis in hyperprostaglandin E-syndrome.Kidney Int. 1993 Aug;44(2):401-10. doi: 10.1038/ki.1993.258. Kidney Int. 1993. PMID: 8377383
-
The role of prostanoids in pediatric diseases employing mass spectrometric techniques.Eicosanoids. 1992;5 Suppl:S4-6. Eicosanoids. 1992. PMID: 1449829 Review.
-
The role of cyclooxygenases and prostanoid receptorsin furosemide-like salt losing tubulopathy: the hyperprostaglandin E syndrome.Acta Physiol Scand. 2004 Aug;181(4):523-8. doi: 10.1111/j.1365-201X.2004.01326.x. Acta Physiol Scand. 2004. PMID: 15283766 Review.
Cited by
-
Congenital nephrogenic diabetes insipidus-vasopressin and prostaglandins in response to treatment with hydrochlorothiazide and indomethacin.Pediatr Nephrol. 1987 Jul;1(3):485-90. doi: 10.1007/BF00849258. Pediatr Nephrol. 1987. PMID: 3153321
-
Neonatal Bartter syndrome.Indian J Pediatr. 2002 Jan;69(1):105-7. doi: 10.1007/BF02723788. Indian J Pediatr. 2002. PMID: 11876110
-
Uncompensated polyuria in a mouse model of Bartter's syndrome.Proc Natl Acad Sci U S A. 2000 May 9;97(10):5434-9. doi: 10.1073/pnas.090091297. Proc Natl Acad Sci U S A. 2000. PMID: 10779555 Free PMC article.
-
Arachidonic acid metabolites and haemodynamics of the neonate.Pediatr Nephrol. 1993 Dec;7(6):841-4. doi: 10.1007/BF01213371. Pediatr Nephrol. 1993. PMID: 8130119 Review.
-
Bartter syndrome complicated by immune complex nephropathy. Case report and literature review.Pediatr Nephrol. 2003 Sep;18(9):913-8. doi: 10.1007/s00467-003-1194-1. Epub 2003 Jun 26. Pediatr Nephrol. 2003. PMID: 12836094 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical